Leo Pharma to market Otrexup in US for Psoriasis

Antares Pharma, Inc., has signed an exclusive promotion and marketing agreement with LEO Pharma for detailing Otrexup ( subcutaneous methotrexate) to dermatologists for symptomatic control of severe recalcitrant Psoriasis in adults in the US. Under the terms of the agreement, Antares may receive up to a total of $20 million in milestone payments including an upfront payment of $5 million. Otrexup was FDA approved for Psoriasis, Rheumatoid Arthritis and Polyarticular Juvenile Idiopathic Aerthritis on 15 October 2013.